期刊
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
卷 44, 期 12, 页码 1258-1262出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.chi.0000181042.29208.eb
关键词
cancer; antidepressants; fluvoxamine; depression
资金
- NIMH NIH HHS [MH63755] Funding Source: Medline
Objective: To evaluate the safety, tolerability, and benefit of fluvoxamine for the treatment of major depressive disorder or anxiety disorders in children and adolescents with cancer. Method: The study was conducted from 2001 to 2004 at a pediatric hematology-oncology center. Fifteen children and adolescents with cancer were treated with fluvoxamine 100 mg/day in an open prospective 8-week trial. Safety and tolerability were evaluated at baseline and at weeks 4 and 8 by blood tests and the Side Effects Checklist. Clinical benefit was assessed with the Clinical Global ImpressionsImprovement, the Children's Depression Rating Scale-Revised, and the Pediatric Anxiety Rating Scale. Results: Fluvoxamine was well tolerated by all subjects. Psychiatric symptoms improved significantly. Conclusions: In this open trial, fluvoxamine appeared to be well tolerated and was associated with a promising reduction in the depression and anxiety symptoms of pediatric patients with cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据